Merck’s $10.8B Prometheus deal delivers another win—plus a Phase 2b miss

The anti-TL1A antibody from Merck's 2023 Prometheus buy delivered positive mid-stage results in a skin condition but failed in a certain type of lung disease, the Big Pharma revealed alongside second-quarter earnings.